Yarrow closes USD 172.5 million offering: BTIG targets Yarrow Bioscience stock at USD 58.00

Published on 10/06/2026 at 10:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Yarrow Bioscience reported USD 0.10 million revenue in the second quarter of 2026. Yarrow Bioscience stock has a USD 188.9 million market value.

YARW, US92941V4077, Illustration mit AI erstellt.

Yarrow Bioscience (US92941V4077) closed a USD 172.5 million public offering on September 14, 2026, while BTIG Research targets Yarrow Bioscience stock at USD 58.00. The financing gives the clinical-stage biotechnology company additional capital for its autoimmune thyroid disease pipeline.

Offering expands development capital

According to StockTitan on September 14, 2026, Yarrow issued 6,634,615 shares at USD 26.00 per share after the underwriters exercised an option for 865,384 additional shares. The gross proceeds were USD 172.5 million, and the company said the funds would support research and development and general corporate purposes.

The earlier underwriting agreement covered 5,769,231 shares at USD 26.00 per share. The SEC filing states that the fully exercised option lifted expected net proceeds to USD 161.8 million.

Losses keep the clinical risk visible

For the second quarter of 2026, revenue was USD 0.10 million, compared with analyst expectations of USD 0.20 million. According to MarketBeat on September 27, 2026, earnings per share were negative USD 3.51, missing the consensus estimate of negative USD 0.18 by USD 3.33.

MarketBeat also reported that BTIG Research began coverage on August 3, 2026, with a Buy rating and a USD 58.00 price objective. The same report cited an overall Hold consensus, with two Buy ratings and one Sell rating, making the target range a material counterweight to the company's current clinical and financing risks.

Market value and trading range

Yarrow Bioscience had a market capitalization of USD 188.9 million as of October 6, 2026. Its 52-week range was USD 16.04 to USD 46.95, placing the company's valuation in a wide band that reflects the early-stage development profile of its autoimmune thyroid programs.